Form 8-K - Current report:
SEC Accession No. 0001140361-23-058292
Filing Date
2023-12-19
Accepted
2023-12-19 07:30:21
Documents
12
Period of Report
2023-12-18
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ef20016870_8k.htm   iXBRL 8-K 28459
  Complete submission text file 0001140361-23-058292.txt   164583

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20231218.xsd EX-101.SCH 3860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20231218_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20231218_pre.xml EX-101.PRE 16041
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20016870_8k_htm.xml XML 4035
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231495633
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)